Description
Elsevier Mosbys 2018 Nursing Drug Reference First South Asia Edition 2017 Edition by Linda Skidmore-Roth
Choose the drug handbook trusted for nearly 30 years! From the leading name in nursing, Mosby's 2018 Nursing Drug Reference is a full-color portable nursing drug handbook that makes it easy to find the most vital information on the drugs that nurses administer most frequently. More than 5,000 drugs are profiled - including 20-30 new entries for drugs recently approved by the FDA. No other drug guide places a higher emphasis on patient safety, with Black Box Warnings for dangerous adverse reactions, Safety Alerts for situations requiring special attention, and a focus on both common and life-threatening side effects. Backed with practical online resources, Mosby's Nursing Drug Reference proves there is a difference in drug guides. It's Mosby's bestselling drug reference for nurses!_x000D__x000D__x000D__x000D_Black Box Warnings provide alerts to FDA warnings of dangerous or life-threatening drug reactions._x000D_Safety Alert icon highlights the most critical drug interactions and side effects._x000D_Common and life-threatening side effects are organized by body system, showing signs to watch for during assessments._x000D_Coverage of IV drug administration highlights dosage and IV administration instructions, including safety considerations and Y-site, syringe, and additive compatibilities._x000D_Alphabetical organization by generic name provides quick and easy access to specific drugs, and a full-color design highlights important information._x000D_Nursing Process steps are used as the framework for organizing all nursing care information. Overview of drug categories explains the safe administration of common classes of drugs, as well as their common side effects and interactions._x000D_Cross-references indicate drug information that may be found in the appendices._x000D_Complete pharmacokinetic information includes the mechanism and absorption of the drug as well as its action, duration, and excretion._x000D_ Table of Contents :- _x000D_
Individual drug monographs_x000D_
_x000D_
Appendixes_x000D_
_x000D_
A. Selected new drugs_x000D_
_x000D_
Antihemophilic factor recombinant, single chain_x000D_
_x000D_
Aspirin/omeprazole_x000D_
_x000D_
Atezolizumab_x000D_
_x000D_
Bezlotoxumab_x000D_
_x000D_
Brivaracetam_x000D_
_x000D_
Cabozantinib_x000D_
_x000D_
Daclizumab_x000D_
_x000D_
Emtricitabine/rilpivirine/tenofovir_x000D_
_x000D_
Emtricitabine/tenofovir_x000D_
_x000D_
Insulin degludec/liraglutide_x000D_
_x000D_
Insulin glargine/lixisenatide_x000D_
_x000D_
Ixekizumab_x000D_
_x000D_
Lixisenatide_x000D_
_x000D_
Nebivolol/valsartan_x000D_
_x000D_
Nivolumab_x000D_
_x000D_
Obiltoxaximab_x000D_
_x000D_
Olaratumab_x000D_
_x000D_
Oxycodone/naltrexone_x000D_
_x000D_
Pimavanserin_x000D_
_x000D_
Reslizumab_x000D_
_x000D_
Sofosbuvir/velpatasvir_x000D_
_x000D_
Venetoclax_x000D_
_x000D_
B. Ophthalmic, nasal, topical, and otic products_x000D_
_x000D_
C. Vaccines and toxoids_x000D_
_x000D_
D. Recent fda drug approvals_x000D_
_x000D_
Index_x000D_